AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

Core Insights - AbbVie and Gubra A/S have entered into a license agreement to develop GUB014295, a long-acting amylin analog aimed at treating obesity, marking AbbVie's entry into the obesity treatment market [1][2][3] - GUB014295 is currently in Phase 1 clinical trials and is designed to activate amylin and calcitonin receptors, which may help suppress appetite and reduce food intake [2][3] - The agreement includes an upfront payment of $350 million to Gubra, with potential milestone payments totaling up to$1.875 billion, along with tiered royalties on global net sales [3] Company Overview - AbbVie is focused on innovative medicines addressing significant health issues, with a mission to transform patient care in areas of unmet need [2][8] - Gubra specializes in preclinical contract research services and peptide-based drug discovery, particularly in metabolic and fibrotic diseases, and reported revenue of DKK 266 million in 2024 [9] Clinical Development - The Phase 1 clinical trial of GUB014295 consists of two parts: Part 1 has been completed, while Part 2 is ongoing, involving a randomized, placebo-controlled design [6][7]